In clinical trials, transcatheter aortic valve replacement (TAVR) has been shown to improve symptoms and quality of life. As this technology moves into general clinical practice, evaluation of the health status outcomes among unselected patients treated with TAVR is of critical importance.
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Supplemental content at jamacardiology.com A lthough the pivotal trials [1] [2] [3] [4] [5] [6] [7] demonstrated survival and quality-of-life (QOL) benefits of transcatheter aortic valve replacement (TAVR) within select cohorts of patients and hospital centers, understanding how this novel technology performs as it moves beyond experienced centers and operators and outside of the strict inclusion and exclusion criteria of the clinical trials is of critical importance. To understand these outcomes more fully, the Society of Thoracic Surgeons (STS) and the American College of Cardiology (ACC) developed the STS/ACC Transcatheter Valve Therapy (TVT) Registry. 8 In the TVT Registry, unselected patients treated with TAVR from January 1, 2011, to December 31, 2013, experienced a 1-year survival rate of 76%, 9 similar to that observed in the pivotal trials. In this elderly population with extensive comorbidity and impaired health status, however, prolonged survival alone (without improved health status) is unlikely to be viewed as a desirable outcome. The importance of improving and maintaining health status after TAVR in these patients has been recognized not only by patients and physicians but also by the Centers for Medicare & Medicaid Services, which requires the collection and monitoring of health status outcomes as part of the national registry. To better understand the full range of benefits of TAVR in clinical practice, we examined the short-and long-term health status outcomes of surviving patients after TAVR in the TVT Registry.
Methods

Study Sample and Protocol
Details of the design, structure, and data elements for the TVT Registry have been published previously. 8, 10 The registry was launched in 2011 as a joint initiative of the STS and ACC and now includes more than 450 clinical sites. Facilities are required to participate in the TVT Registry to obtain Medicare reimbursement; as such, the TVT Registry collects data on nearly all TAVR procedures performed outside clinical trials in the United States. Sites collect data on patient demographics, comorbidities, hemodynamics, functional status, patientreported health status, and outcomes. The TVT Registry has been linked to Medicare administrative claims using direct patient identifiers by the Centers for Medicare & Medicaid Services to evaluate long-term patient outcomes, including hospitalization and survival. 9 Registry activities have been approved by Chesapeake Research Review Incorporated, and the institutional review board of the Duke University School of Medicine granted a waiver of informed consent for this study.
Health Status Assessment and Poor Outcome Definition
The principal health status instrument for the TVT Registry is the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported, disease-specific health status survey developed to describe and monitor symptoms, functional status, and QOL in patients with heart failure 11, 12 ; it has also undergone psychometric testing in patients with severe aortic stenosis. 13 The shortened 12-item version of the KCCQ 14 is collected as part of the TVT Registry at baseline and at 30 days and 1 year after TAVR. The 12-item KCCQ assesses 4 domains related to valvular heart disease: physical limitation, symptom frequency, QOL, and social limitation. These domains are combined into an overall summary score (KCCQ-OS), which is the primary outcome of this study. All domain scores and the KCCQ-OS range from 0 to 100, with higher scores indicating less symptom burden and better QOL. Linguistically and culturally validated translations of the KCCQ were provided to non-English speakers. Congruent with prior studies, the KCCQ-OS scores were categorized as very poor (<25), poor (25-49), fair (50-74), and good (≥75) QOL. 13, 15 Changes in the KCCQ-OS of 5, 10, and 20 points correspond to small, moderate, or large clinical improvements, respectively. 16 To integrate QOL outcomes with survival, a favorable outcome at 1 year after TAVR was defined as survival with a reasonable QOL (KCCQ-OS score ≥60, roughly equivalent to New York Heart Association class I-II symptoms 13, 16 ) without any meaningful worsening (decrease of ≥10 points in the KCCQ-OS score from baseline to 1 year). 17 
Statistical Analysis
Baseline characteristics for the analytic cohort are presented as percentages for categorical variables and medians with interquartile range (IQR) for continuous variables. Unless otherwise indicated, KCCQ scores are reported as mean (SD). Patient mortality risk was estimated using the STS Predicted Risk of Operative Mortality score (the STS mortality risk score), which includes 24 variables and has been validated for predicting inhospital and 30-day mortality after surgical aortic valve replacement. 18 Changes in KCCQ scores from baseline were evaluated at 30 days and 1 year using paired t tests. Mean KCCQ-OS scores at 1 year were compared among key subgroups using analysis of covariance. These comparisons were adjusted for baseline KCCQ-OS scores except for the analysis that was stratified by baseline KCCQ-OS scores. Rates of favorable outcome at 1 year were estimated for each subgroup and compared using χ 2 tests. We then examined factors associated with health status at 1 year after TAVR using multivariable linear regression with generalized estimating equations to account for clustering of patients within sites. Nonlinearity (through use of linear splines) and 2-way interactions were explored and retained in the model at a level of statistical significance of .05 or for clinical importance. As an exploratory analy-
Key Points
Question What is the effect of transcatheter aortic valve replacement on the symptoms, functional status, and quality of life in unselected US patients?
Findings In this national cohort study of 7014 patients undergoing transcatheter aortic valve replacement, surviving patients had, on average, large improvements in health status at 30 days that persisted to 1 year. Worse baseline health status, older age, severe lung disease, home oxygen use, and a lower mean aortic valve gradient were associated with worse long-term health status.
Meaning
The health status benefits of transcatheter aortic valve replacement observed in carefully conducted clinical trials can be extended to the commercial US population undergoing this procedure.
Missing Data
Although KCCQ completion in the TVT Registry has been improving over time, missing data are an important consideration in any QOL analysis. 10 The rate of missing KCCQ data was 18.3% at baseline, 30.6% at 30 days, and 55.7% at 1 year. To ensure that we examined a representative cohort of patients, we first limited our 1-year analyses to sites with at least 50% completion rates for the KCCQ. Second, we examined differences in baseline characteristics between surviving patients with and without 1-year KCCQ data. Third, to reduce the effect of selection bias, we used the inverse probability weighting framework to increase the weight of patients who were most like those with missing follow-up data. 19 This process constructed a multivariable logistic regression model among patients eligible for 1-year follow-up to determine the probability of having missing follow-up KCCQ data. The model included all prespecified patient-level factors and in-hospital major complications. We then weighted each of the patients in the analytic cohort by the inverse probability of the likelihood of having follow-up KCCQ data to better reflect the overall TAVR population. The analysis comparing the health status of patients in key subgroups and the analysis examining factors associated with health status outcomes report the results from this inverse propensity weighting. The rates of missing data on patient-level factors and inhospital major complications were all less than 2% except for the 5-m walk test, which was missing in 13.0%. Missing data were imputed to the most common category for categorical variables and to the median for continuous variables; 5-m walk times were not imputed owing to the degree of missingness. All analyses were performed with SAS software (version 9.4; SAS Institute Inc), and statistical significance was defined as a 2-sided P < .05. . A total of 23 621 patients underwent TAVR and were eligible for 1-year follow-up. After excluding patients from 179 sites with less than 50% rates of KCCQ completion, the 1-year cohort included 7014 surviving patients from 169 sites who completed the KCCQ at baseline and follow-up. Patients who survived 1 year but were missing KCCQ data were more likely to have severe lung disease, higher STS mortality risk scores, and lower baseline KCCQ-OS scores compared with patients in the 1-year analytic cohort (eTable in the Supplement). Median age for the 1-year analytic cohort (the primary analysis) was 84 (IQR, 78-88) years; 3454 (49.2%) were women; 2226 (31.8%) had undergone prior bypass graft surgery; 2547 (36.3%) had diabetes; and 757 (10.8%) were administered home oxygen ( Table 1) . The median STS mortality risk score was 6.2% (IQR, 4.2%-9.4%); the mean aortic gradient was 43 (IQR, 36-52) mm Hg; and 4506 (64.3%) underwent TAVR via a femoral approach.
Results
Study Sample
Baseline Health Status
Among patients in the 30-day cohort, the mean (SD) baseline KCCQ-OS score was 42.3 (23.7) ( Table 2 ). When we examined the subscales of the KCCQ, the QOL domain was the most impaired at a mean score of 33.2 (27.0), indicating that patients reported that their valve disease severely limited their enjoyment of life and that they would be dissatisfied if they had to spend the rest of their lives feeling the same way. The social limitation domain, which describes how patients' valve disease limits their participation in hobbies, household chores, and visiting others, was also severely impaired at a mean score of 39.8 (30.2). The physical limitations domain, which describes the degree to which patients are limited in bathing, walking, or hurrying, showed slightly less impairment at a mean score of 43.2 (27.7). The symptom frequency domain, which quantifies how often the patient had swelling, fatigue, shortness of breath, and orthopnea in the prior 2 weeks, was the least impaired at a mean of 51.8 (26.2).
Short-term Health Status Outcomes
At the 30-day follow-up, KCCQ-OS scores improved by a mean of 27.6 (95% CI, 27.3-27.9) points to a mean score of 69.9 (23.7) ( Table 2 ). On average, each of the individual domains increased by more than 20 points from baseline to 30 days after TAVR, indicating large improvements. The largest improvement was observed in the QOL domain, where the mean improvement was 37.5 (95% CI, 37.1-37.9) points, resulting in a mean score of 70.7 (27.9). The physical limitations domain was least affected by TAVR, with a mean improvement of 21.4 (95% CI, 21.0-21.8) points and a mean 30-day score of 65.1 (28.8), although this change in score represents a large clinical change.
Long-term Health Status Outcomes
One year after TAVR, surviving patients continued to demonstrate substantial improvement in health status, with a mean KCCQ-OS score of 75.9 (21.9) and a mean improvement from baseline of 31.9 (95% CI, 31.3-32.6) points (Table 2 ). Similar to the 30-day results, the lowest domain score at 1 year was for physical limitations, with a mean score of 68.8 (28.4); the remaining domains ranged from 77.0 to 78.6 points. When we integrated survival and QOL, 62.3% of patients had a favorable outcome at 1 year after TAVR. A poor outcome was attributable to death in 19.4%, persistently poor QOL in 17.4%, and a decline in QOL in 4. 
Subgroup Comparisons
We found notable differences in mean 1-year KCCQ-OS scores and the proportion of patients with a favorable outcome across subgroups of patients ( Table 3) . Older age, no prior coronary artery bypass graft, chronic lung disease, low mean aortic gradient, and worse baseline health status were each associated with worse health status after TAVR and lower rates of favorable outcome. Neither kidney function nor access site were associated with health status after TAVR (among survivors); however, patients with chronic renal impairment and patients who required transapical or transaortic access had lower rates of favorable outcomes, mainly owing to increased rates of mortality among these patients. Patients with left ventricular systolic dysfunction had lower rates of favorable outcomes (presumably due to higher rates of death); however, if they survived, they had better long-term health status. We found no statistically significant differences in 1-year KCCQ-OS scores or rates of favorable outcomes according to sex. The lowest rates of favorable outcomes were among patients with severe lung disease (51.4%), those who required dialysis (47.7%), and those with very poor baseline health status (49.2%).
Factors Associated With Health Status at 1 Year
In the multivariable model, patients who had better health status at baseline were more likely to have better health status at 1 year, with every 10-point increase in baseline KCCQ-OS score associated with a 2.5-point higher 1-year KCCQ-OS score (95% CI, 2.2-2.8 points; P < .001) ( Table 4) . Older age was associated with worse 1-year health status, with every 5-year increase associated with a 1.0-point reduction in KCCQ-OS score (95% CI, −1.4 to −0.7 points; P < .001). Higher ejection fraction at baseline, severe lung disease, home oxygen use, lower mean aortic valve gradient, prior stroke, diabetes, permanent pacemaker (before TAVR), atrial fibrillation, and nonfemoral access were also associated with lower 1-year KCCQ-OS scores. In an exploratory analysis among 6151 patients with 5-m b Scores range from 0 to 100, with higher scores indicating less symptom burden and better quality of life.
Discussion
As the use of TAVR expands beyond the pivotal clinical trials to new centers and new patient populations, we must understand the short-and long-term outcomes of these procedures in unselected patients. Although recent studies have demonstrated rates of survival and major complications that are generally consistent with those seen in the original clinical trials, 9 the health status benefits of these procedures-particularly as assessed from the patient's perspective-remain largely unexplored. Given the elderly population who are generally considered for TAVR, understanding the health status outcomes of these procedures is essential.
In this study, we use data from the TVT Registry to explore the health status outcomes among unselected patients undergoing TAVR in current US practices. We found that most patients had substantial impairment in health status before TAVR and demonstrated considerable improvement after the procedure. In particular, by 30 days after TAVR, surviving patients demonstrated large improvements across all domains of the KCCQ, with further, albeit more modest, improvements from 30 days to 1 year. Worse baseline health status, older age, severe lung disease, home oxygen administration, higher baseline ejection fractions, lower mean aortic valve gradient, and slower gait speed were all associated with worse long-term health status. When we examined health status and survival as a composite end point, 38.0% of patients had a poor outcome at 1 year after TAVR, approximately half of which was attributable to death and the other half to persistently poor or worse QOL. Patients with severe lung disease, end-stage renal disease, or very poor baseline health status had the highest rates of poor outcomes, with half being dead or having persistently poor QOL at1year.
Comparison With Prior Studies
The QOL results in the TVT Registry are generally similar to those observed in the clinical trials among patients at high and extreme surgical risk.
2,3,6,7 Nonetheless, several subtle differences in outcomes should be noted between the pivotal trials and the TVT Registry. For example, the changes in the KCCQ-OS at 30 days and 1 year in the TVT Registry of 27.6 and 31.9 points, respectively, are approximately 5 to 10 points greater than those seen in the PARTNER (Placement of Aortic Transcatheter Valve) trial in cohorts A and B 20 and CoreValve US Pivotal Trial. 7 Moreover, the 62.3% rate of favorable outcomes at 1 year in the TVT Registry is modestly higher than seen in the pivotal trials, in which only 50% to 58% of patients were alive with good QOL at 1 year. 7, 20 The reasons for these differences are not entirely clear but may relate to differences between the patients treated in current practice compared with the original trials. In our study, the median STS mortality risk score was less than 7%, which is lower than in the PARTNER and CoreValve pivotal trials. Although undoubtedly some patients treated in the TVT Registry are at even higher risk than those included in the pivotal trials (eg, undergoing dialysis, very low ejection fraction, or low mean gradient), the typical patient treated in current US practice appears to be at somewhat lower risk than the trial participants, with fewer comorbidities that might hinder recovery of QOL after hospitalization. In addition, ongoing improvements in patient selection, procedural techniques, and postprocedural care are likely to have contributed to enhanced health status recovery after TAVR.
In a recent analysis of a German TAVR registry, 21 
Clinical Implications
The present study findings are encouraging and suggest that the benefits of TAVR that have been previously demonstrated within carefully designed and conducted clinical trials can be extended to the commercial TAVR population. In the future, investigating the factors that underlie these outcomes could allow us to maximize the benefits of this ap- a Defined as alive, KCCQ-OS scores of at least 60 (range, 0-100, with higher scores indicating less symptom burden and better quality of life), and no worsening of KCCQ-OS scores from baseline (decline of <10 points).
proach. For example, using risk prediction models to estimate a patient's preprocedure likelihood of a successful outcome may allow clinicians to improve patient selection for TAVR. 20 In addition, such models may be useful in guiding procedural and postprocedural care by targeting patients at increased risk for a poor outcome for less invasive approaches, geriatric consultation, or more intensive rehabilitation and follow-up to help maximize recovery.
Limitations
Our study should be considered in light of the following potential limitations. First, the degree of missing health status data at baseline and follow-up made the analyses challenging. We used several approaches to address this issue, including limiting our analyses to sites with higher rates of complete data and inverse propensity weighting. However, missing data still may have biased our results. Although longitudinal health status data are critical to the understanding of benefit of TAVR, collection of these data in an unselected cohort has been challenging, 22 particularly when no specific reimbursement is provided for data collection. Achieving more complete data will require continued efforts by registry leadership along with a belief by the sites that such data are important.
As such, we hope that these analyses will highlight the importance of health status data for risk estimation and patient selection, 23 assessing response to treatment, and identifying mechanisms to improve care. Second, although we examined several covariates in our multivariable model, some important factors, such as dementia and disability, were not included in the TVT Registry data elements and thus their associations with long-term QOL could not be examined. Third, the long-term QOL results are reported for surviving patients only. Given the high mortality rate after TAVR, the long-term health status benefits of TAVR in particular subgroups could have been missed owing to differential attrition of the sickest patients in the comparator subgroup (eg, renal dysfunction). To address this challenge, we also reported a composite end point that integrates survival and QOL; we believe that examining the results of both analyses is essential to fully understand the benefits of TAVR.
Conclusions
In this national cohort study of unselected US patients undergoing TAVR in clinical practice, we found that, on average, patient health status improved substantially after the procedure. The observed magnitude of health status improvement was similar to that seen in the pivotal clinical trials. Nonetheless, approximately 1 in 3 patients still had a poor outcome at 1 year after TAVR, half of which were attributable to death and half to poor QOL. Therefore, continued efforts to optimize patient selection and refine procedural and postprocedural care to maximize health status recovery are needed to continue to improve the outcomes of these patients. Saving lives is a noble and worthy endeavor, yet the goal of health care is also to alleviate symptoms and improve the quality of remaining years of life. 1 In medicine, our compelling drive to improve survival has left us with a more primitive grasp on symptom and quality-of-life (QOL) outcomes. Quantifying patient-reported outcomes is challenging, because symptoms wax and wane and are subject to variation in reporting and recall. Symptoms often defy precise attribution to underlying cause. In the clinic setting, symptom assessment varies across clinician and patient, and in research, patient-reported outcomes are a tertiary concern. However, nowhere is a scientific approach to symptom assessment more relevant than for those in their mid-80s with severe aortic stenosis (AS) who report symptoms severely limiting their enjoyment of life. In these sick, symptomatic patients, symptomatic improvement is the primary goal of care. Research in the population undergoing transcatheter aortic valve replacement (TAVR) has enlightened our understanding of just how important standardized and complete patient-reported outcomes can be to informing decision making in this setting.
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